Connect with us
deals book
Advertisement
Polaris bank
Advertisement
Oando
Advertisement
Alpha
Advertisement
Hotflex
Advertisement
Binance
Advertisement
Advertisement
UBA
Advertisement
Patricia
Advertisement
Access bank
Advertisement
app

Coronavirus

Pfizer’s COVID-19 vaccine shows positive results

The results encouraged moving to a larger clinical trial to test if the vaccine is actually safe.

Published

on

BioNTech's vaccine, Pfizer, WHO, Partners to deliver 2 billion doses of COVID-19 vaccines, Coronavirus blamed for Monday’s negative performance by Nigerian stocks, Experiment centre requests volunteers to infect with coronavirus and pay them N1.6 million, Airlines cut down capacity to raise capital, as Coronavirus takes a continuous hit at their revenue

An experimental COVID-19 vaccine being created by America’s pharmaceutical giant, Pfizer, and the German firm, BioNTech, activated immune responses in receivers more than individuals naturally recovering from an infection, according to a small journal published online yesterday.

However, the research work has not yet been certified by other medical experts and it is still unknown what degree of immune response will protect an individual from falling sick. Still, medical experts praised Pfizer for publishing the data on 45 people and said the results encouraged moving to a larger clinical trial to test if the COVID-19 vaccine is actually safe and effective for humans.

READ MORE: Measures introduced by Nigeria to ensure transparent use of the $3.4 billion IMF loan

“It’s the first positive data I’ve seen coming out of Operation Warp Speed,” Peter Jay Hotez, dean for the National School of Tropical Medicine at Baylor College of Medicine said to Washington Post, referring to the U.S. government effort to speed up the development, testing, and production of multiple coronavirus vaccines. “I’m really happy Pfizer took the initiative to publish it, whereas the others haven’t. I think we need to see more of this.”

Quick fact about COVID-19: Although for some individuals, the COVID-19 virus causes only mild illness, it can make other individuals seriously ill. The disease can be very fatal, especially among older individuals, and those with compromised immunities (such as diabetes, high blood pressure, or heart problems) appear to be more susceptible.

The 45 individuals were randomly selected in receiving injections of one of three different dose levels of the experimental COVID-19 vaccine. 21 days later, after the initial dose, they got a second one.

READ ALSO: 13,000 BTC wallets are now worth more than $1,000,000

Ugur Sahin, co-founder, and chief executive of BioNTech, told the Financial Times that his firm was going for a higher level of neutralizing antibody responses in order to increase the probability that those individuals vaccinated are prevented from spreading COVID-19 or being infected again.

Hotflex

“If you don’t know the level required to control this virus if you don’t know the power of the enemy, you don’t want the response to be too weak,” Sahin said.

Olumide Adesina is a France-born Nigerian. He is a Certified Investment Trader, with more than 15 years of working expertise in Investment trading. Message Olumide on Twitter @tokunboadesina. He is a Member of the Chartered Financial Analyst Society.

Click to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Business News

COVID-19 Update in Nigeria

On the 7th of May 2021, 39 new confirmed cases were recorded in Nigeria

Published

on

Covid 19 update symptops

The spread of novel Corona Virus Disease (COVID-19) in Nigeria continues to record significant increases as the latest statistics provided by the Nigeria Centre for Disease Control reveal Nigeria now has 165,340 confirmed cases.

On the 7th of May 2021, 39 new confirmed cases were recorded in Nigeria.

To date, 165,340, cases have been confirmed, 155,454 cases have been discharged and 2,065 deaths have been recorded in 36 states and the Federal Capital Territory

A total of 1.94 million tests have been carried out as of 7th May 2021 compared to 1.91 million tests a day earlier.

COVID-19 Case Updates- 7th May 2021,

  • Total Number of Cases – 165,340
  • Total Number Discharged – 155,454
  • Total Deaths – 2,065
  • Total Tests Carried out – 1,939,165

According to the NCDC, the 39 new cases are reported from 8 states- Lagos (23), Abuja (4), Kano (4), Zamfara (4), Akwa Ibom (1), Gombe (1), Nasarawa (1), and Plateau(1).

Meanwhile, the latest numbers bring Lagos state total confirmed cases to 58,547, followed by Abuja (19,806), Kaduna (9,064), Plateau (9,060),Rivers (7,130), Oyo (6,852), Edo (4,902), Ogun (4,678), Kano (3,961), Ondo (3,248), Kwara (3,122), Delta (2,623), Osun (2,575), Nasarawa (2,382), Enugu (2,401), Katsina (2,097), Gombe (2,034), Ebonyi (2,030), Anambra (1,909), Akwa Ibom (1,859), and Abia (1,689).

Imo State has recorded 1,657 cases, Bauchi (1,548), Borno (1,337), Benue (1,188), Adamawa (1,103), Taraba (974), Niger (930), Bayelsa (886), Ekiti (870), Sokoto (775), Jigawa (528), Kebbi (450), Cross River (394), Yobe (390), Zamfara (240), while Kogi state has recorded 5 cases only.

READ ALSO: COVID-19: Western diplomats warn of disease explosion, poor handling by government

Lock Down and Curfew

In a move to combat the spread of the pandemic disease, President Muhammadu Buhari directed the cessation of all movements in Lagos and the FCT for an initial period of 14 days, which took effect from 11 pm on Monday, 30th March 2020.

The movement restriction, which was extended by another two weeks period, has been partially put on hold with some businesses commencing operations from May 4. On April 27th, 2020, Nigeria’s President, Muhammadu Buhari declared an overnight curfew from 8 pm to 6 am across the country, as part of new measures to contain the spread of the COVID-19. This comes along with the phased and gradual easing of lockdown measures in FCT, Lagos, and Ogun States, which took effect from Saturday, 2nd May 2020, at 9 am.

On Monday, 29th June 2020 the federal government extended the second phase of the eased lockdown by 4 weeks and approved interstate movement outside curfew hours with effect from July 1, 2020. Also, on Monday 27th July 2020, the federal government extended the second phase of eased lockdown by an additional one week.

On Thursday, 6th August 2020 the federal government through the secretary to the Government of the Federation (SGF) and Chairman of the Presidential Task Force (PTF) on COVID-19 announced the extension of the second phase of eased lockdown by another four (4) weeks.

Governor Babajide Sanwo-Olu of Lagos State announced the closed down of the Eti-Osa Isolation Centre, with effect from Friday, 31st July 2020. He also mentioned that the Agidingbi Isolation Centre would also be closed and the patients relocated to a large capacity centre.

Due to the increased number of covid-19 cases in Nigeria, the Nigerian government ordered the reopening of Isolation and treatment centres in the country on Thursday, 10th December 2020.

On 26th January 2021, the Federal Government announced the extension of the guidelines of phase 3 of the eased lockdown by one month following the rising cases of the coronavirus disease in the country and the expiration of phase 3 of the eased lockdown.

Jaiz bank

On 28th February 2021, the federal government confirmed that the first tranche of Covid-19 vaccines will arrive in Nigeria on Tuesday, March 2nd, 2021.

On Tuesday, 2nd March 2021, the National Primary health Care Development Agency announced the arrival of the expected COVX Astrazeneca/Oxford covid-19 vaccines.

On Saturday, 6th March 2021, President Muhammadu Buhari and his vice, Yemi Osinbajo received vaccination against the covid-19 as the State House in Abuja.

READ ALSO: Bill Gates says Trump’s WHO funding suspension is dangerous

 

 

app

 

Continue Reading

Coronavirus

Covid-19: WHO approves China’s Sinopharm vaccine

WHO has announced the approval of China’s Sinopharm vaccine for Covid-19 vaccination.

Published

on

Covid-19: First world nations oppose waiving intellectual rights for vaccine development

The World Health Organization (WHO) has announced the approval of China’s Sinopharm vaccine for Covid-19 vaccination.  The vaccine is reported to have 79% efficacy against covid.

This was disclosed today in a report by Reuters. The vaccine would also be the second Chinese-made vaccine after Sinovac vaccine and would be the first developed outside Europe and North America to receive WHO accreditation.

“This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine,” WHO Director-General, Tedros Adhanom Ghebreyesus said.

The WHO added that the easy storage requirements make it highly suitable for low-resource settings.

“Its easy storage requirements make it highly suitable for low-resource settings,” a WHO statement said while also disclosing that the vaccine has been approved for people above the age of 18 to receive two shots.

“On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks,” the statement added.

The vaccine was created by Beijing Biological Products Institute, a subsidiary of Sinopharm subsidiary China National Biotec Group, with an efficacy of 79% for all age groups.

The WHO however, admitted that few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group.

Hotflex

In case you missed it

The quest for vaccine efficiency got a major boost earlier this week as Nairametrics reported that the United States government announced that it supports the waiver of Intellectual Property Protections on Covid-19 vaccine development, in a bid to boost the fight against the pandemic, and says it will participate in the Okonjo-Iweala-led WTO negotiation to make it happen.

Continue Reading

  





Nairametrics | Company Earnings

Access our Live Feed portal for the latest company earnings as they drop.